Curated dataset · n=61 verified deals · Not live market data · Scores are descriptive, not forecasts.
You are here

Deals — Network graph, deal flow, valuation matrix, and acquirer landscape.

Celmatix
→
Gedeon Richter

Acquisition · Cash · RICHTER · announced Mar 3, 2026

View in network
  1. Announced

    Mar 3, 2026

Economics

Undisclosed

Cash

Upfront payment + development milestones (terms not fully disclosed)

Target

Celmatix

Fertility · Clinical / therapeutic

HQ New York, NY · Founded 2009

Women's health biotech — oral FSH receptor agonist for fertility, JNK inhibitor for endometriosis, and AMH antibodies for ovarian aging

  • Gedeon Richter press release (Mar 3, 2026)
  • Budapest Stock Exchange filing
  • Crunchbase - crunchbase.com/organization/celmatix

Acquirer

Gedeon Richter (RICHTER)

Reproductive Health

HQ Budapest, Hungary

Why this buyer

Curated copy from the verified dataset — not an 8-K LLM summary

Women's health drug discovery — oral FSH agonist for fertility, JNK inhibitor for endometriosis, AMH antibodies for ovarian aging; development led by Belgian R&D hub

Evidence ladder

Press only — no primary filingValue undisclosed
  1. Secondary (press / IR)

    Gedeon Richter press release (Mar 3, 2026)

  2. Tertiary (trade / analyst)

    Budapest Stock Exchange filing

Limitations

  • Citations are press/IR only — two wires of the same announcement are not dual-source. Add a primary filing.
  • Deal value not disclosed in verified record; multiples and comparables exclude this transaction.

Valuation peers · Fertility

Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer, until you sort.

Insufficient disclosed data

No verified Fertility deals meet the peer rule: same deal type, announced within ±3 years, and a disclosed value inside 0.25×–4× of this transaction.

Other verified deals by Gedeon Richter

Acquirer program history not already listed as a valuation peer or adjacency row.

Sector
Estetra (Mithra assets)Gedeon RichterJun 12, 2024Contraception

Patient empowerment context

Patient empowerment baseline (HLTH 2022)

No curated mapping — Celmatix (Fertility). HLTH/Outcomes4Me 2022 baseline is Breast cancer care continuum (HLTH 2022). No curated mapping for this target in the verified crosswalk.

Research workspace (includes heuristic crosswalk) →

Related verified workspaces

Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.

Curated verified dataset v11 · updated 2026-10-19 · 2 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.